Today, #LeoInternationalPrecisionHealthAG (LIPH AG) outlined its vision to build a synchronised “Precision Health Engine” designed to transform healthcare from reactive treatment into predictive, personalised and continuous care.
What differentiates LIPH AG is not only the quality of its first six strategic portfolio companies but how these companies reinforce one another within a connected platform model. Within this ecosystem, the future patient journey model would look as follows:
Patients may first enter the ecosystem through 𝗗𝗿 𝗣𝗔𝗜𝗡’𝘀 rehabilitation and pain-management clinics
𝗣𝗮𝘁𝗵𝗼𝗺𝗶𝗰𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 performs precision diagnostics, disease-risk profiling and genomic analysis
𝗮𝗺𝗶𝗸𝗼 𝗔𝗜 acts as the central AI orchestration layer, generating integrated care pathways and predictive health insights
𝗨𝗛𝗢 𝗪𝗲𝗹𝗹𝗻𝗲𝘀𝘀 and 𝗥𝗲𝗻𝗵𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 provide tailored nutraceutical, immune-support and longevity interventions
𝗗𝗮𝗻𝗻𝗲𝗿 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 delivers clinical-grade validation, molecular diagnostics and liquid-biopsy confirmation
Integrated reimbursement and insurance frameworks support continuity of care across the ecosystem.
Individually, each company represents a strategic healthcare asset. Together, they form a scalable Precision Health Engine capable of generating cross-platform synergies.
Management of LIPH AG is convinced that by connecting these capabilities, one can create a scalable healthcare infrastructure where every patient interaction can continuously improve diagnostics, treatment pathways and preventive care.
The Company also announced plans for a second expansion phase across Asia and Europe with combined EBITDA of EUR 50-60 million.
Read the full press release here:
https://lnkd.in/dg6mcXZr
